|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100047114 |
|
最近更新日期: Date of Last Refreshed on: |
2021-06-08 02:43:43 |
|
注册时间: Date of Registration: |
2021-06-08 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
下肢康复机器人对脑卒中患者平衡及步行功能改善及脑重塑机制的研究 |
|
Public title: |
Effects of Lower Extremity Rehabilitation Robot on balance and walking ability and neural plasticity in stroke patients |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
下肢康复机器人对脑卒中患者平衡及步行功能改善及脑重塑机制的研究 |
|
Scientific title: |
Effects of Lower Extremity Rehabilitation Robot on balance and walking ability and neural plasticity in stroke patients |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李飏安 |
研究负责人: |
徐江 |
|
Applicant: |
Yang-An Li |
Study leader: |
Jang Xu |
|
申请注册联系人电话: Applicant telephone: |
15082065251 |
研究负责人电话:
Study leader's |
13971083651 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
m202076127@hust.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
xujiang@hust.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖北省武汉市华中科技大学同济医学院附属同济医院,解放大道1095号 |
研究负责人通讯地址: |
湖北省武汉市华中科技大学同济医学院附属同济医院,解放大道1095号 |
|
Applicant address: |
No.1095 Jie Fang Avenue, Hankou, Wuhan, P.R. China |
Study leader's address: |
No.1095 Jie Fang Avenue, Hankou, Wuhan, P.R. China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
华中科技大学同济医学院附属同济医院 |
||
|
Applicant's institution: |
Tongji Hospital of Tongji Medical College of Huazhong University of Sc |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
[2020]伦审字(S209)-1号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
华中科技大学同济医学院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Tongji Medical College,Huazhong University of Science and Technology |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-01-27 00:00:00 | ||
|
伦理委员会联系人: |
陈汇 |
||
|
Contact Name of the ethic committee: |
Hui Chen |
||
|
伦理委员会联系地址: |
解放大道 |
||
|
Contact Address of the ethic committee: |
Jie Fang Avenue |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
华中科技大学同济医学院附属同济医院康复医学科 |
||||||||||||||||||||||
|
Primary sponsor: |
Department of Rehabilitation Medicine of Tongji Hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖北省武汉市华中科技大学同济医学院附属同济医院,解放大道1095号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.1095 Jie Fang Avenue, Hankou, Wuhan, P.R. China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
深圳市丞辉威世有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shenzhen CHWishay Smart Technology Co., LTD |
||||||||||||||||||||||
|
研究疾病: |
脑卒中 |
||||||||||||||||||||||
|
Target disease: |
Stroke |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
研究下肢康复机器人对脑卒中患者平衡及步行功能改善及脑重塑机制 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the effects of Lower Extremity Rehabilitation Robot on balance and walking ability and neural plasticity in stroke patients |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1) 受试者年龄≥18岁且≤79岁,性别不限;(2) 经CT和/或MRI及临床确诊为脑卒中 ,并仅伴有一侧偏瘫的受试者;(3) 首次发病 ,生命体征平稳,病程:2周-3个月;(4)FAC功能性步行能力量表≥1级;(5) 神志清楚,查体合作,可接受动作指令;(6) 受试者或其监护人能理解研究目的,显示对研究方案足够的依从性,并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) 18-70 years old, male or female;(2) Subjects with stroke diagnosed by CT and/or MRI and clinical diagnosis with one side hemiplegia;(3)First onset, duration of disease: 2 week to 3 month;(4)FAC Level ≥1;(5) No serious cognitive dysfunction, and be able to finish assessment and intervention;(6)Sign the informed consent and participate in the study voluntarily. |
||||||||||||||||||||||
|
排除标准: |
(1) 严重认知功障碍的受试者;(2) 患侧下肢Brunnstrom分期>V级;(3) 患侧下肢改良Ashworth分级(髋、膝、踝)任一≥3级;(4) 严重心脏病、严重且不可控制的高血压、不稳定心绞痛发作、心功能不全Ⅲ级以上、急性心肌梗塞;(5) 下肢局部皮肤损伤者或局部压疮者;(6) 既往有周围神经病的受试者;(7) 既往有癫痫、脊髓损伤、截肢、患侧严重的下肢关节疾病病史者;(8) 受试者存在相关产品使用禁忌证;(9) 有重要脏器功能衰竭或其他严重疾病(包括恶性肿瘤;严重精神病史;活动性的播散性血管内凝血;系统性代谢疾病无法控制)的受试者;(10) 妊娠期或哺乳期或筛选期妊娠试验阳性的女性受试者;(11) 入组前3个月内参加了其他药物或者医疗器械临床试验;(12) 受试者曾有药物滥用史;(13) 已知的因任何原因拒绝或无法依从方案要求(包括计划的临床访视和检查);(14) 研究者出于受试者利益考虑,认为其不应参与本临床试验的其他情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Subjects with severe cognitive function impairment;(2) Brunnstrom stage> V;(3)Modified Ashworth Scale (hip, knee, ankle) of the affected side: any joint≥grade 3;(4) Severe heart disease,hypertension;(5) Local skin injury of lower limbs or local pressure ulcers;(6)A history of peripheral neuropathy;(7)A history of epilepsy, spinal cord injury, amputation, or severe lower limb joint disease;(8) Contraindication for the use of related products;(9) Have vital organ failure or other serious diseases;(10) Pregnant or lactating women;(11) Participated in other clinical trials within 90 days;(12) A history of drug abuse;(13)Inability to effectively communicate with medical staff;(14) Other circumstances considered inappropriate by the researcher to participate in the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-06-01 00:00:00至 To 2022-06-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-06-01 00:00:00 至 To 2022-06-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本试验由独立人员采用分层区组随机方法。用 SPSS 统计软件编程,按中心分层,给定种子数和区组长度,按 1:1 比例将受试者分为试验组和对照组,产生至少60例受试者的随机分组安排,并制定相应的随机信封。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The stratified block random method was used in this experiment by an independent person.The subjects were divided into experimental group and control group according to the ratio of 1:1 according to the center stratification, given the number of seeds and the length of the area. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
邮箱 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The data for the study is available on request to the corresponding author. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |